腹腔镜可调控性胃束带术治疗肥胖伴T2DM的相关机制

Laparoscopic adjustable gastric banding in treatment of obesity accompanying type 2 diabetes

  • 摘要: 目的 探讨腹腔镜可调控性胃束带(LAGB)治疗2型糖尿病(T2DM)的相关机制。方法 肥胖伴T2DM患者20例、单纯性肥胖患者20例行LAGB手术。检测术前、术后第1、3、6、12个月空腹血清Leptin水平,空腹血清胰岛素(FINS)、C肽、糖化血红蛋白(HbA1c)水平,空腹血糖(FBG)水平及体质量并计算体质量指数(BMI)。结果 40例受试者LAGB术后6个月和12个月BMI由术前平均(38±5)kg/m2分别降至(30±4)kg/m2和(28±7)kg/m2(P<0.05)。术前糖尿病组FBG、FINS、胰岛素抵抗指数HOMA-IR=FINS(mU/L)×FBG(mmol/L)/22.5、HbA1c和C肽水平明显高于对照组(P<0.01),术后6个月、12个月FBG由术前(8.5±3.0)mmol/L分别降至(6.5±1.0)mmol/L和(5.9±0.5)mmol/L,FINS和HbA1c术后3个月后降至正常范围。两组患者术后12个月内血清Leptin指标逐渐下降,糖尿病组血清Leptin与FBG、FINS、HbA1c、C肽及HOMA-IR呈正相关。结论 LAGB能有效治疗肥胖症及 T2DM,通过降低血清 Leptin 水平,减轻瘦素抵抗,进而减轻胰岛素抵抗,达到降低血糖的目的。

     

    Abstract: Objective To study the related mechanism of laparoscopic adjustable gastric banding(LAGB) in treatment of type 2 diabetes mellitus(T2DM). Methods Twenty patients with obesity accompanying T2DM and 20 patients with simple obesity underwent LAGB,respectively.Levels of fasting serum leptin,fasting serum insulin,C-peptide,glycated hemoglobin(HbA1c),FBG,as well as body weight and calculating body mass index(BMI) were measured before and 1,3,6,12 months after LAGB. Results The BMI was decreased from 38±5kg/m2 before operation to 30±4kg/m2 and 28±7kg/m2 respectively,6 and 12 month after operation in the 40 patients(P<0.05).The serum levels of FBG,fasting serum insulin,insulin resistance index HOMA-IR= FINS(mU/L)×FBG(mmol/L)/22.5,HbA1c,and C-peptide preoperative levels were significantly higher in patients with T2DM than control group before operation(P<0.01).The FBG levels(8.5±3.0mmol/L) were significantly lower 6 and 12 month(6.5±1.0mmol/L and 5.9±0.5mmol/L) after operation than before operation.The levels of fasting serum insulin and HbA1c returned to normal range 3 month after operation(P<0.01).The serum level of leptin in two groups was gradually declined 12 month after operation.No significant correlation was found between the serum levels of leptin,FBG,fasting serum insulin,HbA1c,C-peptide,HOMA-IR. Conclusion LAGB can effectively treat obesity accompanying T2DM by reducing serum leptin levels,insulin resistance,and blood sugar level.

     

/

返回文章
返回